Relavo offers a device to prevent infection in peritoneal dialysis, a form of at-home treatment for end-stage renal disease.
Relavo has raised $500K in total funding. The most recent round was Seed. The last funding was announced in April 2023.
Relavo's investors include National Science Foundation, MassChallenge, Emmeline Ventures, National Kidney Foundation, San Diego Angel Conference.
Relavo is headquartered in Baltimore, United States.
Relavo offers a device to prevent infection in peritoneal dialysis, a form of at-home treatment for end-stage renal disease.
Relavo is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Relavo — Funding & Investors." VCBacked, April 4, 2023, https://www.vcbacked.co/company/relavo. Accessed July 19, 2026.
VCBacked. (2023). Relavo — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/relavo
{{cite web |title=Relavo — Funding & Investors |url=https://www.vcbacked.co/company/relavo |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated